Abstract

DEVELOPMENT AND CHARACTERIZATION OF LIPID BASED NANOCARRIER SYSTEM FOR THE TARGETING OF ANTI-TUBERCULOSIS DRUG FOR EFFECTIVE MANAGEMENT OF TUBERCOLOSIS

Shardha Kurmi*, Amit Verma, Sunil Kr. Jain and Vivek Jain

ABSTRACT

The aim of the current study is to gauge the development and characterization of Lipid Based Nanocarrier System for the Targeting of Anti-tuberculosis drug for Effective Management of Tubercolosis. In this paper we present general overview of TB including the pathogenesis, diagnosis, and treatment guidelines. Tuberculosis remains one of the deadliest infectious diseases responsible for millions of death annualy across the world. To control tuberculosis, interrupting transmission through effective treatment cannot be overemphasized. The study was conducted to determine factors associated with TB treatment outcome. Demographic characteristics, clinical characteristics, and treatment outcomes were assessed. Bivariate and multivariate logistic regression was conducted to determine the predictors of successful treatment outcome. Results. In case of rifabutin loaded mannosylated solid lipid nanoparticles, 34.71±0.68% of rifabutin was found in liver, where as 24.15±0.42 %, 5.53±0.15 % and 7.97±0.65% were found respectively in lungs, spleen and blood after 24 hours of administration. In case of rifabutin loaded solid lipid nanoparticles, 23.46 ± 0.54% of rifabutin was found in liver, whereas 17.41± 0.45%, 6.11± 0.49% and 10.32± 0.65% were found respectively in lungs, spleen and blood after 24 hours of administration

Keywords: Tuberculosis, Rifabutin, Preformulation studies, Nanocarriers.